DarkIris Inc. Announces Pricing of Initial Public Offering
The Company expects to receive aggregate gross proceeds of US$6.00 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 225,000 Class A ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about August 11, 2025, subject to the satisfaction of customary closing conditions.
Net proceeds from the Offering will be used for: (i) expansion of the operations team and rewards to existing team members; (ii) product development, and (iii) working capital and other general corporate purposes.
The Offering is being conducted on a firm commitment basis. US Tiger Securities, Inc. is acting as the sole book runner for the Offering.
A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-288004), as amended, and was declared effective by the SEC on August 7, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from US Tiger Securities, Inc., Attn: 437 Madison Avenue, 27th Floor, New York, NY 10022, or by email at ecm@ustigersecurities.com, or by calling +1 (646)-978-5188. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About DarkIris Inc.
DarkIris Inc. is a comprehensive technology enterprise based in Hong Kong, engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts. The Company conducts its business through its subsidiaries, Quantum Arts Co., Limited and Hongkong Stellar Wisdom Co., Limited. The Company's activities include game design, programming and graphics, as well as the distribution and operation of mobile games across multiple platforms. DarkIris leverages (i) the innovative, creative and technical expertise of Hong Kong's gaming industry community, and (ii) the multicultural environment and diverse interests of mobile game players in the regions. The Company's goal is to create and promote a broader array of engaging, immersive, and captivating mobile game genres for a global audience. The Company is committed to consistently showcasing exceptional strength and unique allure across diverse gaming sectors, leading the way in pioneering advancements within the industry. For more information, please visit the Company's website: www.darkiris.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'potential,' 'intend,' 'plan,' 'believe,' 'likely to' or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.
For more information, please contact:
DarkIris Inc.Investor Relations DepartmentEmail: dki@darkiris.com
Ascent Investor Relations LLCTina XiaoPhone: +1-646-932-7242Email: investors@ascent-ir.com擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
9 minutes ago
- TechCrunch
Why investors just bet $85M on this Indian company's generic drug strategy
With over 400 million chronic patients, India is one of the world's largest medicine markets. But while most e-pharmacies chase speed, affordability remains the real challenge. Truemeds took a different route: helping patients switch to lower-cost substitutes, a bet now paying off with new funding at about four times its previous valuation. The six-year-old startup has raised $85 million in a new round that includes $65 million in primary and $20 million in secondary funding led by Accel, along with participation from Peak XV Partners. TechCrunch first reported on Accel's talks to back Truemeds last year. Existing investors WestBridge Capital and InfoEdge Ventures, also participated. The fresh round has boosted Truemeds' valuation to over $400 million, up from the $110 million in its last round two years ago. Founded in 2019, Truemeds entered the market at a time when India's online pharmacy space was already crowded with major players offering steep discounts on branded generics. But some of those companies struggled to sustain early momentum — Prosus Ventures-backed PharmEasy, for instance, saw its valuation drop from a peak of $5.6 billion to under $600 million, while 1mg was acquired by Tata Digital, part of the Tata Group. Instead of competing head-on, Truemeds' founders chose to focus on a relatively niche segment: generic medicines. 'There is no way to educate the user that you can have more affordable options if you can't afford these drugs,' said Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. 'That is where we felt that nobody in the value chain was working towards that, and we can bridge that gap.' The Mumbai-based recommends generic alternatives to consumers for the branded medicines they need. This eventually helps consumers save money, as generic drugs are typically more affordable than their branded versions due to cost efficiencies in their development process. Truemeds says its differentiated approach has paid off, with revenue growing over 66% year-over-year to ₹5 billion ($57 million) in the last financial year. The startup says it retains more than 15% of its revenue after 12 months and now serves an average of 500,000 customers each month, with a total of 3 million customers to date. Moreover, it says it now serves over 20,000 postal codes across the country, with more than 75% of its customers coming from tier-2 cities and beyond. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW However, educating customers about alternatives to their prescribed medicines — and convincing them to switch from branded drugs to generics — remains a challenge. 'Because you get anchored to your prescribed brand's price, and when you suddenly see a lower price, you want to know why it is low,' Nayyar told TechCrunch. Increasing discounts while competitors cut back While today's e-pharmacies chase speed over savings, the sector's early playbook was different. Online pharmacies in India used to offer discounts of up to 25% to attract customers. However, Nayyar said this dropped to 20% and then 15% — the new average — as most burned cash to acquire new customers and pivoted to faster delivery as their main differentiator. Meanwhile, Truemeds has gone in the opposite direction, increasing its average discounts from 29% to 32% in the last 12 months. For an average user who switches brands on the platform, savings reach 47% on their medicine, says the company. This comes from Truemeds' deep procurement relationships with pharma companies, where the startup uses its technology to give manufacturers better demand visibility, helping them plan production more efficiently for upcoming quarters, he said. The startup also relies on its own logistics in some of the major cities it operates in and uses low-cost logistics partners for the rest. 'We believe that our four-hour delivery model is more than sufficient from a chronic patient's perspective,' said Nayyar. 'You're able to do more planned purchases that way, but we want to do it in the most efficient manner, and pass more and more discounts to the end user rather than [focus on] the fastest delivery for that matter.' Next up: AI-powered customization and doorstep diagnostics As Truemeds needs to convince customers to choose generics over branded medicines, it goes through deeper consultations with them. It already conducts 10-12 million consultations per year. The startup has developed an algorithm over the years that looks at various parameters to precisely suggest alternatives to the branded drugs a customer demands. It considers nuances such as whether the medicine is sugar-coated if it is for a young patient, where it is manufactured, and whether the plant is GMP-certified, among others. The startup also has a chatbot to address some user queries quickly. Much more is on the roadmap. The company plans to develop an AI-based system that customizes conversations based on customers' behavior and previous interactions with generic alternatives. It's also opening a Bengaluru office while dedicating at least 20% of its capital to engineering and product development. Beyond medicines, Truemeds is plotting to enter diagnostics through partnerships with national pathology labs, planning to pilot lab testing services in some tier-2 cities in the next three to four months. 'The primary mission remains the same, which is making healthcare affordable for the end user,' the co-founder said. 'It started with medicines. Now that the model is getting established, we are going to keep scaling that. Simultaneously, we also want to see if we can do something similar on the diagnostics front, where we can be the lowest cost provider of at least the most common tests.' The startup also plans to increase its fulfillment center count by 300% — from 19 currently — over the next 12 months, aiming to deepen its presence in existing markets. Before this round, Truemeds raised $50 million and still has 30–35% of that capital in the bank, Nayyar said. The startup has a workforce of 2,800 people, with 250 based in its Mumbai office.
CNBC
10 minutes ago
- CNBC
Asia markets set for a mixed open as U.S.-China tariff truce deadline looms
Asia-Pacific markets were set to open mixed as traders awaited announcement on whether the Aug. 12 deadline for U.S.–China tariff truce would be extended. Happy Monday from Singapore. Asia markets were poised for a mixed open. Australia's S&P/ASX 200 was set to start the day lower with futures tied to the benchmark at 8,768, compared with the index's last close of 8,807.1. Futures for Hong Kong's Hang Seng Index stood at 24,937, pointing to a higher open compared with the HSI's last close of 24,858.82. Japan markets are closed for a holiday. — Lee Ying Shan Visitors visit the NVIDIA booth at the 3rd China International Supply Chain Expo in Beijing, China, on July 20, 2025. Nurphoto | Nurphoto | Getty Images Chip giant Nvidia pushed back Sunday in response to allegations from Chinese state media that its H20 artificial intelligence chips are a national security risk for China. Earlier in the day, Reuters reported Yuyuan Tantian, an account affiliated with Chinese state broadcaster CCTV, said in an article published on WeChat that the Nvidia H20 chips are not technologically advanced or environmentally friendly. "When a type of chip is neither environmentally friendly, nor advanced, nor safe, as consumers, we certainly have the option not to buy it," the Yuyuan Tantian article reportedly said, adding that the article said chips could achieve functions including "remote shutdown" through a hardware "backdoor." In response, a Nvidia spokesperson told CNBC that "cybersecurity is critically important to us. NVIDIA does not have 'backdoors' in our chips that would give anyone a remote way to access or control them." Nvidia on Tuesday rejected similar accusations. For more, read here. — Pia Singh
Wall Street Journal
10 minutes ago
- Wall Street Journal
Oil Falls Amid Easing Supply-Disruption Concerns
2338 GMT — Oil falls in the early Asian session amid easing concerns about supply disruptions. U.S. President Trump said Friday he would meet with Russian President Putin in Alaska on Aug. 15 after Putin presented the Trump administration with a proposal for a cease-fire in Ukraine. Geopolitical risks have eased, ANZ Research analysts say in a research report, citing the news. Also, U.S. tariffs have officially commenced, raising worries over weaker economic activity and hence, demand for crude oil, the analysts add. Front-month WTI crude oil futures are down 0.4% at $63.64/bbl; front-month Brent crude oil futures are 0.3% lower at $66.37/bbl. (
